FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.02
+0.41 (+2.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.61
Open15.81
Bid0.00 x 3000
Ask0.00 x 800
Day's Range15.14 - 16.05
52 Week Range8.35 - 19.11
Volume485,807
Avg. Volume642,591
Market Cap1.042B
Beta (3Y Monthly)3.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire4 days ago

    Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu, M.D. has joined the Company as Vice President, Clinical Development. Dr. Chu brings extensive experience in the development of cancer immunotherapies from Genentech, a member of the Roche Group, where he most recently served in Product Development Oncology as global development leader of mosunetuzumab, a full-length T cell-dependent bispecific CD20/CD3 antibody. Dr. Chu will be responsible for leading clinical development of the Company’s induced pluripotent stem cell (iPSC)-derived, cell-based cancer immunotherapy programs.

  • GlobeNewswire20 days ago

    Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient treated with FT500 successfully completed an initial safety assessment. The patient received three once weekly doses of FT500, and the treatment cycle was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period. The universal, off-the-shelf natural killer (NK) cell product candidate is the first-ever cell therapy derived from an induced pluripotent stem cell (iPSC) administered to a patient in the U.S.

  • GlobeNewswire21 days ago

    Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today presented late-breaking preclinical data highlighting the Company’s unmatched ability to mass produce uniformly engineered chimeric antigen receptor (CAR) T cells for off-the-shelf cancer immunotherapy at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia (LB-073/18: Generation of Novel Single Cell-derived Engineered Master Pluripotent Cell Line as a Renewable Source for Off-the-shelf TCR-less CAR T Cells in support of First-of-kind Clinical Trial). The Company’s proprietary approach to CAR T-cell therapy utilizes a one-time genetic modification event followed by high-throughput selection of a single gene-edited induced pluripotent stem cell (iPSC).

  • GlobeNewswirelast month

    Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss, Ph.D. has been appointed to the Company’s Board of Directors. Dr. Jooss has more than 20 years of experience in oncology and immunology research and development, and is currently the Executive Vice President of Research and Chief Scientific Officer of Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next-generation cancer immunotherapies targeting tumor-specific neoantigens.

  • GlobeNewswire2 months ago

    Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

    First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in.

  • ACCESSWIRE2 months ago

    Fate Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Fate Therapeutics, Inc. (NASDAQ: FATE) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 5, 2019 at 5:00 PM ...

  • GlobeNewswire2 months ago

    Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results

    SAN DIEGO, Feb. 28, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 22, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire2 months ago

    Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley, M.D., M.S., a leading expert in the field of natural killer (NK) cell receptor immunogenetics and in the clinical development of NK cell cancer immunotherapies, has joined the Company as Senior Vice President, Clinical Translation. Dr. Cooley brings to Fate Therapeutics more than 12 years of leadership in the field of NK cell clinical research and development, having most recently served as Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota.

  • GlobeNewswire2 months ago

    Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day

    SAN DIEGO, Feb. 07, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire2 months ago

    Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel CD16 Fc receptor. FT516 is the first-ever cell therapy derived from a genetically engineered pluripotent stem cell cleared for clinical testing in the world, and is the Company’s second off-the-shelf, iPSC-derived NK cell product candidate cleared for clinical investigation by the FDA within the past two months.

  • GlobeNewswire5 months ago

    Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. Last week, the Company announced that the U.S. Food and Drug Administration (FDA) allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master iPSC line.

  • GlobeNewswire5 months ago

    Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive option to an intellectual property portfolio owned by the Max Delbrück Center for Molecular Medicine (MDC) covering novel humanized chimeric antigen receptor (CAR) constructs that uniquely and specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    How Healthcare Is Evolving & Sector Stocks To Watch

    CORAL GABLES, FL / ACCESSWIRE / November 30,2018 / The Global Connected Healthcare Market was valued at USD $1,860.26 million in2017, and is expected to grow at a CAGR of 28.3% by 2025. There has been a growing increase in the use of smartphones by physicians leading to a practice of digital health. The global digital health market is expanding at a fast pace.

  • GlobeNewswire5 months ago

    Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. The clinical trial of FT500 is expected to be the first-ever clinical investigation in the U.S. of an iPSC-derived cell product.

  • GlobeNewswire5 months ago

    Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500

    SAN DIEGO, Nov. 11, 2018 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new clinical data for FATE-NK100, an investigational, first-in-class, allogeneic donor-derived natural killer (NK) cell cancer immunotherapy, and provided a regulatory update on the development of FT500, a universal, off-the-shelf NK cell product candidate derived from a master induced pluripotent stem cell (iPSC) line, on November 10, 2018. Twenty heavily pre-treated subjects, each presenting with progressive disease at the time of enrollment, have been treated with FATE-NK100 in the dose-escalation phases of three Phase 1 clinical trials.

  • GlobeNewswire5 months ago

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 08, 2018 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire6 months ago

    Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

    Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed.

  • GlobeNewswire6 months ago

    Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting

    Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN.

  • ACCESSWIRE6 months ago

    3 Healthcare Stocks To Watch On Thursday

    CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.